傣雅解护肝方对D-氨基半乳糖致小鼠急性肝损伤的保护作用

目的：研究傣雅解护肝方对D-氨基半乳糖致小鼠急性肝损伤模型的保护作用。方法：小鼠经傣雅解护肝方预防性灌胃给药7天后,腹腔注射D-氨基半乳糖造模,24小时后检测小鼠血清谷丙转氨酶（ALT）、谷草转氨酶（AST）活性及显微镜观察小鼠肝组织病理学变化。结果：傣雅解护肝方各剂量组能明显抑制D-氨基半乳糖致小鼠急性肝损伤模型ALT、AST的升高（P〈O．05或P〈0．01）;减轻D-氨基半乳糖对肝脏细胞的病理损伤。结论：傣雅解护肝方对D-氨基半乳糖所致小鼠急性肝损伤有明显的保护作用。     

新生牛肝细胞生长因子对大鼠急性肝衰竭影响的初步研究

参照Labrecque等提取肝细胞刺激物质(HSS)的方法,从新生牛肝脏中提取出分子量小于1.98万u的生物活性物质,动物试验表明,该物质对D-氨基半乳糖(D-Gal)所致的急性肝衰竭大鼠的存活率有明显的提高,并对大鼠肝细胞DNA合成有明显的促进作用。     

沙苑子黄酮对CCl4及D-氨基半乳糖致急性肝损伤的保护作用

目的探讨沙苑子黄酮(FAC)对肝损伤的保护作用。方法采用0.1?l4(10mL/kg)、D-氨基半乳糖(D-Gal,700mg/kg)分别ip造成小鼠急性肝损伤模型,并ig不同剂量的FAC,测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)活性,观察肝组织病理改变;用CCl4损伤原代培养大鼠肝细胞,测定细胞培养液ALT、AST活性,MTT法测定肝细胞增殖活性。结果FAC能显著降低小鼠CCl4和D-Gal损伤原代培养大鼠肝细胞模型ALT和AST活性(P<0.01),病理学观察显示,FAC明显减轻肝组织损伤程度(P<0.01)。FAC显著提高肝细胞活性,促进肝细胞增殖。结论FAC具有显著的保肝作用。     

溪黄草提取物预防大鼠急性肝损伤的实验研究

目的:研究溪黄草提取物对大鼠急性肝损伤的预防作用。方法:以不同剂量的溪黄草提取物灌胃给药7d,末次给药后1 h以四氯化碳(CC l4)及D-胺基半乳糖(D-Gal)造成大鼠急性肝损伤模型,24 h后眼眶取血,分离血清,测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)活性,观察溪黄草提取物的作用。结果:溪黄草提取物低、中、高剂量组的ALT、AST活性与造模组比较,均有显著性差异。结论:溪黄草提取物具有良好的预防大鼠急性肝损伤的作用。     

Complementary innate (anti-A-specific) IgM emerging from ontogenic O-GalNAc-transferase depletion: (Innate IgM complementarity residing in ancestral antigen completeness)

The murine and the human genome have global properties in common. So the murine anti-A-specific complementary IgM and related human innate isoagglutinin represent developmental, 2-mercaptoethanol-sensitive, complement-binding glycoproteins, which do not arise from any measurable environmentally-induced or auto- immune response. The murine anti-A certainly originates from a cell surface- or cell adhesion molecule, which in the course of germ cell development becomes devoid of O-GalNAc-transferase and is released into the circulation. In human sera the enzyme occurs exclusively in those of blood group A- and AB subjects, while in group O(H) an identically encoded protein lets expect an opposite function and appears in conjunction with a complementary anti-A reactive glycoprotein. Since O-glycosylations rule the carbohydrate metabolism in growth and reproduction processes, we propose that the ancestral histo-(blood)-group A molecule arises in the course of O-GalNAc-glycosylations of glycolipids and protein envelops at progenitor cell surfaces. Germ cell development postulates embryonic stem cell fidelity, which is characterised by persistent production of α-linked O-GalNAc-glycans. They are determined by the A-allele within the human, “complete” histo (blood) group AB(O) structure that in early ontogeny is hypothesised to be synthesised independently from the final phenotype. The structure either passes “completely” through the germline, in transferase-secreting mature tissues becoming the “complete” phenotype AB, or disappears in exhaustive glycotransferase depletion from the differentiating cell surfaces and leaves behind the “incomplete” blood group O-phenotype, which has released a transferase- and O-glycan-depleted, complementary glycoprotein (IgM) into the circulation. The process implies, that in humans the different blood phenotypes evolve from a “complete” AB(O) molecular complex in a distinct enzymatic and/or complement cascade suggesting O-glycanase involvements. While the murine and human oocyte zona pellucida express identical O-glycans, the human phenotype O might be explainable by the kinetics of the murine ovarian O-GalNAc glycan synthesis and the complementary anti-A released in parallel. The maturing murine ovary may provide insight into encoding of the physiologically superior α-linked GalNAc ancestral epitope that becomes essential in reproduction as well as in tissue renewal events. According to recent reports, O-GalNAc-transferase-determined blood group A suggests superiority in human female fertility and was called even “protective”. So the minor fertility of blood-group-O females may reside in a critical timing in developmental shifting of enzyme functions affecting the formation of GalNAc-determined hormone receptors on the way to maturation. Experiments that had inserted an oocyte genome into a somatic one to generate pluripotent stem cells, might elucidate a developmental dilemma by testing oocytes from different blood group AB donors donors. Perhaps they will unmask the molecular basis of an evolutionary trend, while stem cell generation itself capitalises on the enzymatically-advantaged, lineage-maintaining (histo) blood group A-allele, which guaranties ancestral functional completeness.     

阿尔茨海默病大鼠模型复制的实验研究

目的:探讨阿尔茨海默病大鼠模型的复制方法.方法:大鼠腹腔注射D-半乳糖(D-Gal)造成急性衰老,同时大鼠双侧海马内缓慢一次性注射β淀粉样蛋白1-42片段(Aβ1-42)和Ibo的混合液来制作阿尔茨海默病大鼠的模型.结果:光镜观察可见模型组大鼠海马神经细胞之间有大量的老年斑(SP)沉积和神经纤维缠结(NFT)形成,大鼠行为学检测结果提示:模型组大鼠与正常组大鼠相比平均逃避潜伏期明显延长.结论:腹腔注射D-Gal,双侧海马内注射Aβ1-42和Ibo混合液,能引起大鼠学习记忆能力下降,并使神经组织中出现SP及NFT,是现在较为理想的阿尔茨海默病动物模型的复制方法.     

姜黄素对小鼠实验性肝损伤的保护作用

目的 :探讨姜黄素对肝脏损伤的保护作用。方法 :分别建立四氯化碳、D-半乳糖胺及卡介苗加脂多糖诱导小鼠肝脏损伤模型 ,以测定血清谷丙氨酸转换酶 (ALT)、谷草氨基酸转换酶 (AST)、一氧化氮 (NO)和肝匀浆丙二醛 (MDA)含量为指标观察姜黄素对肝脏损伤的保护作用。结果 :姜黄素与阳性对照药联苯双酯相仿 ,均能明显降低动物模型的血清ALT ,AST ,NO和肝匀浆MDA含量。结论 :姜黄素具有明显的保肝作用。     

田基黄对大鼠急性肝损伤的保护作用

目的:研究田基黄对大鼠急性肝损伤的保护作用。方法:采用CC l4及D-氨基半乳糖(D-Gal)致大鼠急性肝损伤模型,观察田基黄提取液对肝损伤大鼠血清谷丙转氨酶(ALT)、谷草转氨酶(AST)活性的影响。结果:田基黄对CC l4及D-Gal所致的大鼠血清ALT、AST活性升高有明显的抑制作用。结论:田基黄对大鼠急性肝损伤具有保护作用。     

D-半乳糖诱导大鼠骨髓基质细胞衰老及其机制

目的构建大鼠骨髓基质细胞(BMSCs)体外和体内衰老模型,观察BMSCs衰老生物学特性。方法体外对照组:常规培养大鼠骨髓BMSCs,取第三代(P3)细胞继续培养48 h;体外衰老组:在对照组基础上加入D-半乳糖(D-Gal,终浓度30 g/L),作用48 h;体内衰老组:大鼠皮下注射D-Gal(120 mg/kg·d),qd×42 d;体内对照组:注射等时等量0.9%氯化钠溶液,模型完成第2天,分离培养BMSCs,取P3细胞进行实验。检测:CCK-8测定细胞增殖;流式细胞术分析周期和凋亡率;β-半乳糖苷酶(SA-β-Gal)染色观察BMSCs衰老百分率;DCFH-DA荧光流式细胞术检测活性氧簇(ROS)水平,酶学法检测过氧化物丙二醛(MDA)含量和总超氧化物歧化酶(SOD)活性;Western blot检测P16、P21、P53、CDK2和cyclin D表达。结果 D-Gal体外与体内致衰老组BMSCs增殖能力下降;细胞G0/G1期比例增高、S期比例降低(P0.05);SA-β-Gal染色阳性百分率上升(P0.05);胞内ROS、MDA上升,SOD下降(P0.05);P16、P21、P53表达上调,CDK2、cyclin D下调(P0.05)。结论 D-Gal在体内与体外均能构建BMSCs衰老模型,其机制与D-Gal诱导BMSCs氧化损伤和激活衰老信号途径相关。